Who Paid My Doc
Barbara Rizzardi
Internal Medicine Sandy, UT Medical Doctor
NPI 1245385319 CMS profile 55965
1434 E 9400 S, #208, Sandy, UT 84093
General payments
$29,886
Research payments
$253,783
Ownership & investment interest
$0
Research they led as principal investigator
$27,788,012
Through program year 2025, Barbara Rizzardi of Sandy, UT is reported in the CMS Open Payments database as having received $29,886 across 171 general payments and $253,783 in research payments paid to them. Separately, studies naming them as principal investigator received $27,788,012 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
11 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $15,359 | 21 | |
| 2025 | Research | $4,225 | 18 | |
| 2024 | General | $3,029 | 17 | |
| 2024 | Research | $2,486 | 14 | |
| 2023 | General | $6,683 | 42 | |
| 2023 | Research | $620 | 1 | |
| 2022 | General | $82 | 3 | |
| 2022 | Research | $246,452 | 17 | |
| 2021 | General | $28 | 1 | |
| 2020 | General | $225 | 10 | |
| 2019 | General | $4,481 | 77 |
Beside peers
- Barbara Rizzardi
- Internal Medicine median
- Middle half of Internal Medicine
- National median
In program year 2025, general payments to Barbara Rizzardi were reported at $15,359. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.
Show as a table
| Year | Barbara Rizzardi | Internal Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,481 | $159 | $48–$570 | $163 |
| 2020 | $225 | $119 | $33–$402 | $114 |
| 2021 | $28 | $135 | $37–$521 | $132 |
| 2022 | $82 | $141 | $42–$496 | $149 |
| 2023 | $6,683 | $149 | $45–$519 | $160 |
| 2024 | $3,029 | $154 | $47–$537 | $164 |
| 2025 | $15,359 | $156 | $47–$551 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
221 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Internal Medicine in Utah
Willard Dere
Internal Medicine · Salt Lake City, UT
Kenneth Schaecher
Internal Medicine · West Valley City, UT
Steven Call
Internal Medicine · Springville, UT
James Chamberlain
Internal Medicine · Salt Lake City, UT
Alexander Pastuszak
Internal Medicine · Salt Lake City, UT
Zameer Abedin
Internal Medicine · Salt Lake City, UT
Related records
Internal Medicine in Utah
Practitioners in the same specialty and state, ranked by reported value.
All Internal Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Utah
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.